SLA2

Across TCGA pan-cancer cohorts, SLA2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLA2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD are the cancer types where SLA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	1.000	0.284	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SLA2–LUAD (DFS)

Open the LUAD breakdown →